117 related articles for article (PubMed ID: 18955814)
1. Isolation and structure determination of a proteasome inhibitory metabolite from a culture of Scytonema hofmanni.
Shim SH; Chlipala G; Orjala J
J Microbiol Biotechnol; 2008 Oct; 18(10):1655-8. PubMed ID: 18955814
[TBL] [Abstract][Full Text] [Related]
2. Proteasome structure, function, and lessons learned from beta-lactone inhibitors.
Groll M; Potts BC
Curr Top Med Chem; 2011 Dec; 11(23):2850-78. PubMed ID: 21824111
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of the ubiquitin-proteasome system by natural products for cancer therapy.
Tsukamoto S; Yokosawa H
Planta Med; 2010 Aug; 76(11):1064-74. PubMed ID: 20186654
[TBL] [Abstract][Full Text] [Related]
4. Drug discovery and assay development in the ubiquitin-proteasome system.
Berkers CR; Ovaa H
Biochem Soc Trans; 2010 Feb; 38(Pt 1):14-20. PubMed ID: 20074028
[TBL] [Abstract][Full Text] [Related]
5. Hofmannolin, a cyanopeptolin from Scytonema hofmanni PCC 7110.
Matern U; Oberer L; Erhard M; Herdman M; Weckesser J
Phytochemistry; 2003 Nov; 64(6):1061-7. PubMed ID: 14568072
[TBL] [Abstract][Full Text] [Related]
6. Covalent and non-covalent reversible proteasome inhibition.
Beck P; Dubiella C; Groll M
Biol Chem; 2012 Oct; 393(10):1101-20. PubMed ID: 23091276
[TBL] [Abstract][Full Text] [Related]
7. A template-based approach to inhibitors of calpain 2, 20S proteasome, and HIV-1 protease.
Jones SA; Neilsen PM; Siew L; Callen DF; Goldfarb NE; Dunn BM; Abell AD
ChemMedChem; 2013 Dec; 8(12):1918-21. PubMed ID: 24130198
[TBL] [Abstract][Full Text] [Related]
8. Proteasome inhibition in multiple myeloma: therapeutic implication.
Chauhan D; Hideshima T; Anderson KC
Annu Rev Pharmacol Toxicol; 2005; 45():465-76. PubMed ID: 15822185
[TBL] [Abstract][Full Text] [Related]
9. Isolation of chlorine-containing antibiotic from the freshwater cyanobacterium Scytonema hofmanni.
Mason CP; Edwards KR; Carlson RE; Pignatello J; Gleason FK; Wood JM
Science; 1982 Jan; 215(4531):400-2. PubMed ID: 6800032
[TBL] [Abstract][Full Text] [Related]
10. The persisting challenge of selective and specific proteasome inhibition.
Groll M; Huber R; Moroder L
J Pept Sci; 2009 Feb; 15(2):58-66. PubMed ID: 19109822
[TBL] [Abstract][Full Text] [Related]
11. Towards the control of intracellular protein turnover: mitochondrial Lon protease inhibitors versus proteasome inhibitors.
Bayot A; Basse N; Lee I; Gareil M; Pirotte B; Bulteau AL; Friguet B; Reboud-Ravaux M
Biochimie; 2008 Feb; 90(2):260-9. PubMed ID: 18021745
[TBL] [Abstract][Full Text] [Related]
12. The carmaphycins: new proteasome inhibitors exhibiting an α,β-epoxyketone warhead from a marine cyanobacterium.
Pereira AR; Kale AJ; Fenley AT; Byrum T; Debonsi HM; Gilson MK; Valeriote FA; Moore BS; Gerwick WH
Chembiochem; 2012 Apr; 13(6):810-7. PubMed ID: 22383253
[TBL] [Abstract][Full Text] [Related]
13. Capillary electrophoresis for screening of 20S proteasome inhibitors.
Chen W; Mou K; Xu B; Ling X; Cui J; Xu P
Anal Biochem; 2009 Nov; 394(1):62-7. PubMed ID: 19615965
[TBL] [Abstract][Full Text] [Related]
14. Indole Alkaloids of the Stigonematales (Cyanophyta): Chemical Diversity, Biosynthesis and Biological Activity.
Walton K; Berry JP
Mar Drugs; 2016 Apr; 14(4):. PubMed ID: 27058546
[TBL] [Abstract][Full Text] [Related]
15. Proteasome inhibition: mechanism of action.
DeMartino GN
J Natl Compr Canc Netw; 2004 Nov; 2 Suppl 4():S5-9. PubMed ID: 19791423
[TBL] [Abstract][Full Text] [Related]
16. Pharmaceutical agents from filamentous marine cyanobacteria.
Tan LT
Drug Discov Today; 2013 Sep; 18(17-18):863-71. PubMed ID: 23711931
[TBL] [Abstract][Full Text] [Related]
17. [Design, synthesis and biological assay of novel tripeptidic tetrazoles as inhibitors of 20S proteasome].
Ma YH; Xu B; Cui JR; Yang ZJ; Zhang LR; Zhang LH
Yao Xue Xue Bao; 2012 Apr; 47(4):472-8. PubMed ID: 22799029
[TBL] [Abstract][Full Text] [Related]
18. Proteasome regulators: activators and inhibitors.
Huang L; Chen CH
Curr Med Chem; 2009; 16(8):931-9. PubMed ID: 19275603
[TBL] [Abstract][Full Text] [Related]
19. Proteasome inhibitors mechanism; source for design of newer therapeutic agents.
Harer SL; Bhatia MS; Bhatia NM
J Antibiot (Tokyo); 2012 Jun; 65(6):279-88. PubMed ID: 22511225
[TBL] [Abstract][Full Text] [Related]
20. Novel proteasome inhibitors to overcome bortezomib resistance.
Ruschak AM; Slassi M; Kay LE; Schimmer AD
J Natl Cancer Inst; 2011 Jul; 103(13):1007-17. PubMed ID: 21606441
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
